Publication Year
2018
Jensen IS, Wu E, Sacks NC, Cyr PL, Chung KC. 2018. Budget impact analysis of using daunarubicin-cytarabine liposome in patients with newly diagnosed therapy-related AML or AML and myelodysplasia-related changes. Am Health Drug Benefits 11(7):380–386, open access online.